drugset / Trial / NCT05850286
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD(Bortezomib, Lenalidomide and Dexamethasone)-based regimen combined with CART-ASCT-CART2 in patients with newly diagnosed multiple myeloma with p53 gene abnormalities.
Timeline
- Start
- 2023-04-21
- Primary completion
- 2026-04-15
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |
| Subject | anti-BCMA CAR-T | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | anti-BCMA CAR-T | Cell therapy | 4e+06 cells/kg | Intravenous |